HMPL-506, a novel, highly potent and differentiated menin-MLL inhibitor for the treatment of MLL-rearranged and NPM1mutant acute leukemia in preclinical models程敏,和黄医药,中国上海#2113
海报展示 | Poster Session (PO.ET07.02 – Pharmacodynamic Biomarkers of Drug Response)
2024年4月8日(星期一)新型 CD38 靶向抗体偶联药物 (ADC) HMPL-A067 (HMA800067) 在临床前 B 细胞恶性肿瘤模型中表现出优于达雷妥尤单抗的抗肿瘤活性
HMPL-A067 (HMA800067), a novel CD38-targeting antibody-drug conjugate (ADC), demonstrated superior anti-tumor activity to daratumumab in preclinical B-cell malignancies models许艳,和黄医药,中国上海#1890
海报展示 | Poster Session (PO.ET01.02 – Antibody-Drug Conjugates and Bispectific Antibodies)
2024年4月8日(星期一)HMPL-295 (一种强效、选择性的 ERK1/2 抑制剂) 的临床前特征
Preclinical characterization of HMPL-295, a potent and selective ERK1/2 inhibitor胡佳,和黄医药,中国上海#1661
海报展示 | Poster Session (PO.MCB03.01 – Cell Signaling Components as Therapeutic Targets)
2024年4月8日(星期一)靶向 YAP1/TEAD信号通路使 KRAS 驱动的肿瘤细胞对 MAPK/ERK 通路抑制剂重新敏感
Targeting YAP1/TEAD signaling re-sensitizes MAPK/ERK pathway inhibitors in KRAS-driven cancer cells杨贤雯,和黄医药,中国上海#1931
海报展示 | Poster Session (PO.ET03.04 – Drug Resistance 2: Ras GTPase)
2024年4月8日(星期一)Syk 抑制剂索乐匹尼布 (HMPL-523) 在复发或难治性淋巴瘤患者中的安全性和有效性
Safety and Efficacy of Sovleplenib (HMPL-523), a Syk Inhibitor, in Patients with Relapsed or Refractory LymphomaPaolo Strati, The University of Texas MD Anderson Cancer Center, USA#CT144
海报展示 | Poster Session (PO.CT01.03 – Phase 0 and Phase I Clinical Trials)
2024年4月8日(星期一)早期癌胚抗原 (CEA) 动态预测呋喹替尼 + 最佳支持治疗在FRESCO-2 研究中入组的转移性结直肠癌患者的疗效
Early carcinoembryonic antigen (CEA) dynamics to predict the efficacy of fruquintinib (F) + best supportive care (BSC) in patients with metastatic colorectal cancer (mCRC) enrolled in FRESCO-2Stefano Lonardi, Veneto Institute of Oncology IOV-IRCCS Padua, Italy#6408
海报展示 | Poster Session (PO.CL01.10 – Predictive Biomarkers 5)
2024年4月9日(星期二)赛沃替尼+奥希替尼对比赛沃替尼+ 安慰剂,用于治疗奥希替尼治疗后进展的 EGFR 突变 、MET 扩增的晚期非小细胞肺癌患者
Savolitinib (savo) + osimertinib (osi) vs savo + placebo (PBO) in patients (pts) with EGFR-mutated (EGFRm), MET-amplified advanced NSCLC with progression on osi杨志新,国立台湾大学医学院附设医院癌医中心分院,中国台北#CT251
海报展示 | Poster Session (Session PO.CL01.10 – Predictive Biomarkers 5)
2024年4月9日(星期二)研究者发起的临床试验通过ROS依赖性铁死亡增强抗癌疗效: 索凡替尼和顺铂在小细胞肺癌中的协同作用
Enhanced anticancer efficacy via ROS-dependent ferroptosis: synergy between surufatinib and cisplatin in small cell lung cancer李晓林,南京医科大学附属医院,中国南京#2122
海报展示 | Poster Session (PO.ET07.02 – Pharmacodynamic Biomarkers of Drug Response)
2024年4月8日(星期一)索凡替尼治疗非小细胞肺癌的疗效及作用机制
Efficacy and underlying mechanisms of surufatinib in non-small cell lung cancer treatment郑燕芳,广州医科大学附属肿瘤医院,中国广州#2126
海报展示 | Poster Session (PO.ET07.02 – Pharmacodynamic Biomarkers of Drug Response)
2024年4月8日(星期一)增强胆管癌的放射敏感性: 索凡替尼在肿瘤抑制和巨噬细胞重新编程中的双重作用
Enhancing Radiosensitivity in Biliary Tract Cancer: The Dual Role of Surufatinib in Tumor Suppression and Macrophage Reprogramming马虹,武汉协和医院,中国武汉#2127
海报展示 | Poster Session (PO.ET07.02 – Pharmacodynamic Biomarkers of Drug Response)
2024年4月8日(星期一)索凡替尼治疗胰腺癌: 揭示GPR34在肿瘤相关巨噬细胞及增强免疫疗法疗效中的作用
Surufatinib treatment in pancreatic cancer: unveiling the role of GPR34 in TAMs and enhancing immunotherapy efficacy郝继辉/高松,天津医科大学肿瘤医院,中国天津#2128
海报展示 | Poster Session (PO.ET07.02 – Pharmacodynamic Biomarkers of Drug Response)
2024年4月8日(星期一)索凡替尼联合PD-1单抗和化疗治疗胰腺癌的疗效及作用机制
Efficacy and Underlying Mechanisms of Surufatinib Combined with PD-1 Monoclonal Antibody and Chemotherapy in Pancreatic Cancer戴广海/ 贾茹,中国人民解放军总医院,中国北京#2129
海报展示 | Poster Session (PO.ET07.02 – Pharmacodynamic Biomarkers of Drug Response)
2024年4月8日(星期一)优化放射疗法联合VEGFR-TKI和PD-(L)1抑制剂治疗转移性结直肠癌的治疗方案
Optimizing the treatment schedule of radiotherapy combined with VEGFR-TKIs and PD-(L) 1 inhibitors in metastatic colorectal cancer张涛/ 林振宇,华中科技大学同济医学院附属协和医院肿瘤中心,中国武汉#3827
海报展示 | Poster Session (PO.CL10.04 – Outcome Investigation with Real World Data)
2024年4月8日(星期一)神经内分泌分化的临床和流行病学概况 — 一项基于医院的回顾性研究
Clinical and epidemiological profile of neuroendocrine differentiation- A hospital-based retrospective study石素胜/文亚茹,中国医学科学院肿瘤医院,中国北京#4630
海报展示 | Poster Session (PO.ET06.04 – Molecular Classification of Tumors for Diagnostics, Prognostics, and Therapeutic Outcomes)
2024年4月9日(星期二)神经内分泌分化型胃癌的流行病学特征及治疗策略
Epidemiological characteristics and treatment strategies of gastric cancer with neuroendocrine differentiation (NED)张军,重庆医科大学附属第一医院,中国重庆#4864
海报展示 | Poster Session (PO.PS01.08 – Descriptive Epidemiology and Statistical and Epidemiological Methodology)
2024年4月9日(星期二)索凡替尼联合信迪利单抗和 IBI310 治疗高级别晚期神经内分泌肿瘤患者的初步疗效: 一项多中心、单臂II 期研究
Initial efficacy of surufatinib plus sintilimab and IBI310 for patients with high-grade advanced-neuroendocrine neoplasm: A multicenter, single arm phase 2 study沈琳/ 陆明,北京大学肿瘤医院,中国北京#CT266
海报展示 | Poster Session (PO.CT02.02 -Phase II Clinical Trials 2)
2024年4月9日(星期二)